SCN5A Variant K1264N
Summary of observed carriers, functional annotations, and structural context for SCN5A K1264N. Data combine curated literature, international cohorts, and gnomAD observations.
Estimated LQT3 penetrance
5%
0/11 effective observations
Estimated BrS1 penetrance
7%
0/11 effective observations
Total carriers
1
0 BrS1 · 0 LQT3 · 1 unaffected
Variant features alone are equivalent to phenotyping 0 individuals for Brugada syndrome and 0 individuals for LQT3.
In silico predictors
PROVEAN | PolyPhen-2 | BLAST-PSSM | REVEL | Penetrance Density BrS (%) | Penetrance Density LQT3 (%) |
---|---|---|---|---|---|
-2.77 | 0.757 | 0.33 | 0.63 | 3 | 2 |
PROVEAN scores below -2 suggest deleterious impact. REVEL scores above 0.5–0.75 are often interpreted as likely pathogenic. PolyPhen-2 scores above 0.85 are typically pathogenic. Penetrance density summarises neighbouring residue risk (Kroncke et al. 2019).
Reported carrier data
Source | Year | Carriers | Unaffected | LQT3 | BrS1 | Other | Other Disease |
---|---|---|---|---|---|---|---|
Literature, cohort, and gnomAD | – | 1 | 1 | 0 | 0 | – | |
Variant features alone | – | 15 | 15 | 0 | 0 | – | – |
Totals may differ from individual publications due to duplicate patients removed during curation.
Nearby variants
Neighbouring residues within 15 Ångström provide structural context. Variants listed in the right-most column have been observed clinically or in gnomAD.
Neighbour residue | Distance (Å) | Observed variants |
---|---|---|
1264 | 0 | K1264N, K1264R, K1264N, |
1267 | 9 | |
1270 | 14 | A1270S, |
1262 | 5 | G1262S, |
1259 | 11 | |
1257 | 13 | |
1268 | 8 | T1268S, T1268N, T1268S |
1265 | 4 | |
1258 | 12 | |
1269 | 11 | N1269S, |
1272 | 12 | |
1266 | 9 | |
1260 | 11 | A1260D, |
1261 | 8 | |
1263 | 6 | |
1273 | 14 | W1273C, W1273C, c.3816delG, |